Pricing Log in Create free account
Saturday 7 November 2026 Export VTVT’s income statement to Excel — free account

vTv Therapeutics Inc.

VTVT Healthcare Biotechnology

vTv Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, down 49.6% from fiscal 2022.

Revenue
+409,222.2%
EPS
−14.1%
Free cash flow
−124.6%

Quarter to June 2026, against a year earlier

21.26 0.48 −2.21%
Market cap
$86.0M
P/E
0.0×
Fwd P/E
−8.2×
Dividend yield
—
F-score
n/a
Altman Z
−10.00
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 83.40%

Capital & Financial Ratios $m

Size
Market Cap 85.96
Revenue ttm 37.87
Net income ttm (6.40)
Free cash flow ttm (16.76)
Net debt Q (86.64)
Valuation
P/E 0.00
Forward P/E (8.15) (negative: loss-making)
Price / sales 6.97
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.36
Financial health
Current ratio Q 12.48 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (7,885.00)
Growth
Revenue growth Q +409,222.22% (above 0%: growing)
Operating income growth Q −80.42% (below 0%: shrinking)
EPS, this year +62.25% (at or above 15%: strong)
EPS, next year A −243.31% (below 0%: weak)
Revenue, next year A +293.31% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A −12.78% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.7×, against a ten-year median of 13.9×; over the ten years it ranged from −65.6× in 2016 to 3,329× in 2020.
P/S against its own 10 years 15.73%
10-year low 10-year high
EV/Sales against its own 10 years 12.60%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9 37 89 87
Receivables 0 0 — —
Inventory — — — —
Other 0 0 0 1
11 38 90 88
2023 2024 2025 Q'26
Payables 10 5 7 7
ST’ Debt — — — —
Other 0 — 0 0
11 5 7 7

Compound Annual Growth %

10y 5y 3y
Sales 0.41% (39.39%) (45.88%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.75 Actual −1.05

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.97 −1.08 Miss by 0.11
Q4 FY25 −0.98 −0.58 Beat by 0.40
Q1 FY26 0.34 1.65 Beat by 1.31
Q2 FY26 −0.75 −1.05 Miss by 0.30
Q3 FY26 −1.07 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 1.65 (1.05) — — —
’25 (0.77) (0.92) (1.08) (0.58) (3.20)
’24 (1.17) (0.81) (0.88) (0.51) (3.20)
’23 (2.40) (2.80) (3.20) (1.67) (9.71)
’22 (4.00) (1.60) (2.00) (2.40) (10.40)
’21 (3.20) (0.40) (0.80) (4.40) (8.40)
’20 (4.40) (2.80) (1.20) 0.80 (7.20)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 37 — — — —
’24 1 — — 0 1
’22 2 0 — 0 2
’21 1 0 3 0 4
’20 0 — 0 6 6
’19 1 2 0 0 3
’18 2 2 3 5 12
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 9 (11) — — —
’25 (6) (5) (5) (9) (25)
’24 (7) (7) (6) (5) (25)
’23 (5) (6) (5) (3) (19)
’22 (1) 1 (9) (7) (16)
’21 (5) (4) (4) (6) (19)
’20 (6) (5) (5) (2) (18)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 9 (11) — — —
’25 (6) (5) (5) (9) (25)
’24 (7) (7) (6) (5) (25)
’23 (5) (6) (5) (3) (19)
’22 (1) 1 (9) (7) (16)
’21 (5) (4) (4) (6) (19)
’20 (6) (5) (5) (2) (18)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 0 12 3 6 4 2 — 1 — 38 +6.1% 31 31 31 0.0%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00 — 99.92 0.0 pt
EBT (55) (54) (24) (22) (13) (18) (25) (26) (23) (31) (6) (6.2%)
EBT margin, % (8,730.76) (18,504.12) (190.16) (790.09) (199.59) (439.85) (1,232.56) 0.00 (2,222.71) 0.00 0.00 +8,730.8 pt
Net income (55) (55) (24) (22) (13) (18) (25) (26) (23) (31) (6) (6.2%)
Per share, $
Per share, $ Revenue 2.66 1.20 39.96 3.65 5.44 2.56 1.05 0.00 0.18 0.00 0.00 n/m
Earnings (68.40) (66.80) (27.60) (23.60) (7.20) (8.40) (10.40) (9.71) (3.20) (3.20) (0.77) (28.8%)
Cash flow (201.96) (183.90) (86.30) (30.39) (15.27) (12.33) (8.35) (9.15) (4.39) (3.00) (1.35) (37.4%)
Capex (0.35) (0.10) 0.02 0.32 0.00 0.00 (0.01) 0.00 0.00 0.00 0.00 n/m
Free cash flow (202.31) (184.01) (86.28) (30.08) (15.27) (12.33) (8.36) (9.15) (4.39) (3.00) (1.35) (37.4%)
Book value (381.00) (623.39) (266.24) (64.73) (67.97) (6.22) (5.59) (11.84) 2.48 7.65 6.34 n/m
Shares, m 0 0 0 1 1 2 2 2 6 8 10 +48.6%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 — 0.00 0.0
P/S 75.75 201.83 2.65 18.63 13.66 15.56 27.43 — 77.00 — 6.97 54.1
P/B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 5.57 — 3.36 0.7
EV/Sales 11.96 213.50 3.03 18.48 12.97 12.55 22.12 — 42.82 — 4.72 42.2
EV/FCF (0.16) (1.39) (1.40) (2.24) (4.69) (2.64) (2.78) — (1.74) — (10.59) (2.1)
Cash, $m
Cash, $m Operating cash flow (48) (45) (27) (23) (18) (19) (16) (19) (25) (25) (17) (6.9%)
Capex 0 0 0 0 — — 0 — — — 0 (20.5%)
Free cash flow (48) (45) (27) (23) (18) (19) (16) (19) (25) (25) (17) (6.9%)
Balance, $m
Balance, $m Working capital 41 (7) (15) (11) 1 7 19 0 33 83 81 +8.3%
Net debt (40) 3 5 (2) (6) (13) (12) (9) (37) (89) (87) +9.1%
Shareholders’ equity (91) (151) (83) (49) (80) (10) (11) (25) 14 64 79 n/m
Returns, %
Returns, % ROA (22.40) (39.18) (47.43) (146.36) (70.66) (64.51) (65.28) (91.51) (74.92) (42.09) (8.34) (19.7) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 19.36 13.34 7.40 19.78 13.16 28.91 187.15 114.34 355.76 (68.52) (11.74) (87.9) pt
People
People Employees 51 56 52 26 25 9 13 16 23 26 — (7.2%)
Revenue/emp, $m 0.01 0.01 0.24 0.11 0.26 0.45 0.16 0.00 0.04 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Mar 2026 · fundamentals updated 25 Oct 2026

vTv Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SEER Seer, Inc. $90.3M — (loss-making) — (loss-making) −23.43% (below 0%: shrinking) n/m +36.73% (above 0%: growing) 48.55% (542.91%) Compare
RTSN Retension Pharmaceuticals, Inc. $89.3M — — — — — — — Compare
CBUS Cibus, Inc. $87.1M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%) Compare
PLYX Polaryx Therapeutics, Inc. $86.7M — (loss-making) — — n/m −93.09% (below 0%: shrinking) — 0.00% Compare
MIST Milestone Pharmaceuticals Inc. $86.2M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
VTVT vTv Therapeutics Inc. $86.0M — (loss-making) — (loss-making) +409,222.22% (above 0%: growing) n/m −124.59% (below 0%: shrinking) 100.00% 0.00%
RLYB Rallybio Corporation $84.5M 3.3× — (loss-making) 0.00% n/m +65.25% (above 0%: growing) 100.00% 0.00% Compare
EQ Equillium, Inc. $84.3M — (loss-making) — (loss-making) −52.32% (below 0%: shrinking) n/m −38.67% (below 0%: shrinking) 100.00% 0.00% Compare
GNLX Genelux Corporation $82.4M — (loss-making) — (loss-making) — n/m −11.18% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $86.5M — — −23.43% — −11.18% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 April 2026

Ownership

Directors and executive officers, together 5.99%
MacAndrews & Forbes 38.13%
Samsara BioCapital GP, LLC 9.99%
Trails Edge 9.99%
Invus PE 9.43%
JDRF T1D Fund LLC 8.52%
G42 Investments AI Holdings RSC, Ltd. 6.59%
Millennium Group 5.71%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

vTv Therapeutics Inc. (VTVT) Latest News

5 Nov

Impact 3 · · GlobeNewswire

27 Oct

Impact 3 ·

20 Oct

Impact 4 · · MarketBeat

10 Oct

Impact 3 · · GlobeNewswire

8 Oct

Impact 3 · · Investing.com

7 Oct

Impact 4 · · GlobeNewswire

6 Oct

Impact 3 · · GlobeNewswire

5 Oct

Impact 3 · · GlobeNewswire

17 May

Impact 3 · · Simply Wall St.

15 May

Impact 3 · · Zacks

13 May

Impact 3 · · GlobeNewswire

20 Apr

Impact 3 ·

17 Mar

Impact 3 ·
Impact 3 · · Zacks

10 Mar

Impact 3 ·
Impact 3 · · GlobeNewswire

3 Mar

Impact 4 · · Insider Monkey

2 Feb

Impact 3 ·

5 Jan

Impact 4 · · Barchart

24 Dec

Impact 4 · · ZacksZacksZacksZacksZacks

19 Dec

Impact 3 · · Simply Wall St.

18 Dec

Impact 4 · · GlobeNewswire

11 Nov

Impact 4 · · Zacks

6 Nov

Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire

9 Oct

Impact 3 · · GlobeNewswirePharmaceutical TechnologyExec EdgeInsider MonkeyMT NewswiresPharmaceutical TechnologyZacksPharma Voice

15 Sep

Impact 3 ·

2 Sep

Impact 4 ·

12 Aug

Impact 3 · · Associated Press Finance
Impact 3 · · GlobeNewswire
stockrow.com/VTVT · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com